Cargando…

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

BACKGROUND: In Canada, two vaccines that have demonstrated high efficacy against infection with human papillomavirus (HPV) types −16 and −18 are available. The HPV-6/11/16/18 vaccine provides protection against genital warts (GW) while the HPV-16/18 vaccine may provide better protection against othe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kohli, Michele, Lawrence, Donna, Haig, Jennifer, Anonychuk, Andrea, Demarteau, Nadia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503751/ https://www.ncbi.nlm.nih.gov/pubmed/23061913 http://dx.doi.org/10.1186/1471-2458-12-872

Ejemplares similares

Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years
por: Kim, Young-Jae, et al.
Publicado: (2010)

Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors
por: Damm, Oliver, et al.
Publicado: (2009)

Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2019)

Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18
por: Bogaards, Johannes A, et al.
Publicado: (2019)

Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule
por: Germar, Maria Julieta, et al.
Publicado: (2017)

Erratum to: Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2020)

Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix
por: Costa, Ana Paula Ferreira, et al.
Publicado: (2018)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Impact of malaria and helminth infections on immunogenicity of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Tanzania()()
por: Brown, Joelle, et al.
Publicado: (2014)

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
por: Vokó, Zoltán, et al.
Publicado: (2012)

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study
por: Einstein, Mark H, et al.
Publicado: (2014)

Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine
por: Folschweiller, Nicolas, et al.
Publicado: (2019)

Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: Interim analysis of a large community-randomized controlled trial
por: Lehtinen, Matti, et al.
Publicado: (2016)

The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10–16 years
por: Nakalembe, Miriam, et al.
Publicado: (2014)

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study
por: Folschweiller, Nicolas, et al.
Publicado: (2020)

Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
por: Bonanni, Paolo, et al.
Publicado: (2015)

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial
por: Leung, Ting Fan, et al.
Publicado: (2015)

Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus–Based Screening in Mexico
por: Torres-Ibarra, Leticia, et al.
Publicado: (2019)

Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment
por: Hildesheim, Allan, et al.
Publicado: (2016)

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
por: Szarewski, Anne, et al.
Publicado: (2013)

Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience
por: Angelo, Maria-Genalin, et al.
Publicado: (2014)

Evaluation of the detection of 14 high-risk human papillomaviruses with HPV 16 and HPV 18 genotyping for cervical cancer screening
por: BIAN, MEI-LU, et al.
Publicado: (2013)

Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification?
por: Sung, Yeoun Eun, et al.
Publicado: (2016)

Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women
por: Ramanakumar, Agnihotram V, et al.
Publicado: (2010)

Frequency of Human Papillomavirus (HPV) 16 and 18 Detection in Paraffin- Embedded Laryngeal Carcinoma Tissue
por: Hosseini, Seyed Zinab, et al.
Publicado: (2017)

Primary Screening for Cervical Cancer Based on High-Risk Human Papillomavirus (HPV) Detection and HPV 16 and HPV 18 Genotyping, in Comparison to Cytology
por: Agorastos, Theodoros, et al.
Publicado: (2015)

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males: Profile Report
por: Garnock-Jones, Karly P., et al.
Publicado: (2012)

Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand
por: Khunamornpong, Surapan, et al.
Publicado: (2016)

Effectiveness of the AS04‐adjuvanted HPV‐16/18 vaccine in reducing oropharyngeal HPV infections in young females—Results from a community‐randomized trial
por: Lehtinen, Matti, et al.
Publicado: (2019)

Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody
por: Peng, Shiwen, et al.
Publicado: (2021)

Barriers to human papillomavirus (HPV) vaccination among young adults, aged 18–35
por: Muthukrishnan, Meera, et al.
Publicado: (2022)

Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
por: Schwarz, Tino F., et al.
Publicado: (2017)

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials
por: Wacholder, Sholom, et al.
Publicado: (2010)

The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples
por: Song, Fangbin, et al.
Publicado: (2020)

Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women
por: Kim, Seung Cheol, et al.
Publicado: (2011)

Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme
por: Angelo, Maria-Genalin, et al.
Publicado: (2014)

Variants of human papillomaviruses 16 (HPV16) in Uigur women in Xinjiang, China
por: He, Hongchang, et al.
Publicado: (2016)

Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years
por: Bi, Dan, et al.
Publicado: (2019)

Human papillomavirus (HPV) 16 infection is not detected in rectal carcinoma
por: Martins, Sandra F., et al.
Publicado: (2020)

Meta‐analysis of the risk of autoimmune thyroiditis, Guillain‐Barré syndrome, and inflammatory bowel disease following vaccination with AS04‐adjuvanted human papillomavirus 16/18 vaccine
por: Rosillon, Dominique, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jqnnqebijbi4p38vb9agjclr85